Greetings,
We are excited to share this limited submission opportunity from St. Baldrick's Childhood Cancer Research Foundation. The St. Baldrick's Foundation is committed to supporting the most promising research to find cures for childhood cancers and give survivors long and healthy lives. Harvard may put forward one nomination for this funding opportunity (see Limited Submission Details below for an exception to this rule). More information about the award and the internal selection process can be found in the synopsis and links below. For a full list of currently open opportunities that have been announced through our office, please visit our Current Opportunities web page. As a reminder, our Research Development team is available to provide proposal development support to FAS ladder faculty.
- Harvard Pre-Proposal Deadline: September 20, 2026 at 11:59 PM ET
- OSP Deadline, if selected: Not applicable at the Letter of Intent (LOI) stage
- Sponsor Deadline, if selected: October 16, 2026 at 5:00 PM ET
- Award Amount: Up to $100,000/year for two years
No institutional overhead or indirect funding is provided under the terms of the grant. This falls short of the 15% overhead required by FAS/SEAS policy. Please discuss this with your grants administrator before preparing an application.
Program Overview
Since making its first grants as an independent charity in 2005, the St. Baldrick’s Foundation has invested more than $380 million in childhood cancer research grants worldwide. Research Grants are for specific two-year research projects with direct applicability and relevance to pediatric cancer, which are hypothesis driven and may be laboratory, clinical, or epidemiological in nature. For the 2027 cycle, St. Baldrick’s has added a LOI review process for Research Grants. Harvard's nominee will submit an LOI, which St. Baldrick’s will evaluate for mission alignment and scientific merit. The Foundation will invite selected applicants to submit a full proposal.
Priority Areas
- Current funding priorities are divided into four categories:
- New discovery research
- Translational research and early phase clinical trials
- Phase III clinical trials & infrastructure support of participating institutions
- Education of new pediatric oncology researchers
- In addition to research to understand the biology of childhood cancers and discover leads to more effective treatments, topics of interest include, but are not limited to:
- Adolescents & young adults
- Survivorship, outcomes, and quality of life
- Supportive care
- Epidemiology and pediatric cancer predispositions
- Precision medicine
- Alternative & complementary therapies
Eligibility Criteria
- Research Grant applicants should hold a Ph.D., M.D., or D.O. degree in a field of research specialty by the date the award becomes effective (July 1, 2027).
- Applicants need not be American citizens; however, they must work at an academic, medical, or research institution within the United States.
- St. Baldrick’s funds may not be used for human embryonic stem cell research.
- Co-Investigators/Co-Principal Investigators are allowed on Research Grants. The LOI/application is required to be submitted under one lead Principal Investigator.
Harvard Pre-Proposal Materials
- PI name, title, primary appointment, and CV (NIH Biosketch format)
- Co-PI(s) name, title, appointment, as applicable
- Proposal title
- Research project proposal focus area
- Research focus keyword(s), three (3) to five (5)
- Rationale for the proposed research project (300 words, max.)
- Abstract/summary, prepared for a general/lay audience (1 page, 11 pt. font in Times New Roman)
Limited Submission Details
This is a limited submission opportunity and Harvard may only submit one application; schools located on either campus of Harvard University are viewed as a single institution (though Harvard affiliated hospitals and institutions are viewed as separate). However, due to high interest from donors and low numbers of past applications, one additional LOI/application will be accepted only if it focuses on one of the areas listed below. This allowance applies to the overall cycle—not to each funding category individually (e.g., Research Grant, International Scholar Award, Survivorship & Supportive Care Research Grant):
- Rhabdomyosarcoma
- Brain tumors –especially atypical teratoid/rhabdoid tumor (AT/RT), diffuse intrinsic pontine glioma (DIPG)/diffuse midline glioma (DMG), and glioblastoma (GBM)
- Burkitt lymphoma – all types, especially sporadic
- Rhabdoid tumors - Extrarenal
The Office of the Vice Provost for Research will conduct an internal competition to select Harvard’s nominee. To be considered for a Harvard nomination, potential applicants must submit an internal pre-proposal by 11:59 PM on September 20, 2026, via the link above.
Additional Information and Resources
Interested applicants are encouraged to review the full Information and Guidelines for Research Grant Awards, the FAQs, and an article which discusses the review process. Applicants may also search for recent funding recipients in St. Baldrick's Foundation's grantee database.
For the 2027 cycle, St. Baldrick’s has added a LOI review process for Research Grants. Harvard's nominee will submit an LOI, which St. Baldrick’s will evaluate for mission alignment and scientific merit. The Foundation will invite selected applicants to submit a full proposal. LOI decisions will be announced by December 15, 2026, and those selected to advance will be invited to submit a full proposal due March 5, 2027. Award decisions will be announced by June 26, 2027 for a July 1, 2027 award start date.
Questions from FAS or SEAS faculty about this opportunity may be directed to FAS Research Development.
Requests for support related to the application portal may be directed to the Office of the Vice Provost for Research. |